Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | APOB | P04114 | 9/20 | 0.44 |
| ▸ | MTTP | P55157 | 9/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792032 | 1.00 | PTGS1 (0.48) | PTGS1APOBMTTPTRPV1SMN1; SMN2 | |
| SCHEMBL6792701 | 0.86 | MTTP (0.49) | PTGS1APOBMTTPTRPV1SMN1; SMN2 | |
| SCHEMBL6792704 | 0.86 | MTTP (0.49) | PTGS1APOBMTTPTRPV1SMN1; SMN2 | |
| SCHEMBL6793187 | 0.80 | PTGS1 (0.49) | PTGS1APOBMTTPTRPV1SMN1; SMN2 | |
| SCHEMBL6794206 | 0.80 | LMNA (0.60) | PTGS1APOBMTTPSMN1; SMN2 | |
| SCHEMBL6792997 | 0.80 | TP53 (0.49) | PTGS1APOBMTTPSMN1; SMN2KDM4E | |
| SCHEMBL6794628 | 0.80 | PTGS1 (0.48) | PTGS1APOBMTTPSMN1; SMN2KDM4E | |
| SCHEMBL3886439 | 0.78 | PTGS1 (0.53) | PTGS1APOBMTTPSMN1; SMN2 | |
| SCHEMBL3886435 | 0.78 | PTGS1 (0.53) | PTGS1APOBMTTPSMN1; SMN2 | |
| SCHEMBL6788456 | 0.78 | OPRL1 (0.48) | PTGS1APOBMTTPSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | PTGS1 1382/4885APOB 1/4885MTTP 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.